The role of perioperative intravenous low-dose dexamethasone in rapid recovery after total knee arthroplasty: a meta-analysis
This report has been verified
by one or more authors of the
original publication.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2021;9(9):13 J Int Med Res. 2021 Mar;49(3): 300060521998220.What this means for my practice?
Pooled results of this meta-analysis of randomized controlled trials in patients undergoing a primary total knee arthroplasty suggest that administering peri-operative low-dose dexamethasone can help improve pain, range of motion, incidence of post-operative nausea and vomiting, and consumption of opioids up to 24 and 48-hours post-surgery compared to placebo or no treatment. However, this study had several limitations including the lack of long-term follow-up, lack of subgroup analysis for different dexamethasone administrations, which varied by study, and high heterogeneity for some outcome analyses (i.e., blood glucose levels at 72-hours, opioid consumption at 24-hours, overall range of motion). Another limitation is that only 1 study was included in the analysis for active range of motion at 72-hours. Therefore, future randomized controlled trials should aim to address these limitations in order to confirm the findings of this meta-analysis.
Study Summary
Ten randomized controlled trials containing a total of 1100 patient knees were included in this meta-analysis comparing peri-operative low-dose dexamethasone administration to placebo in patients undergoing total knee arthroplasty (TKA). Primary outcomes of interest included pain using the visual analogue scale (VAS) at 24 and 48 hours post-surgery, incidence of complications, immediate range of motion (ROM), and incidence of post-operative nausea and vomiting (PONV). Secondary outcomes included the following: total consumption of opioids at 24 and 48 hours, length of hospital stay, and blood glucose levels. Pooled results demonstrated that VAS pain at 24 and 48 hours post-TKA were statistically significantly reduced in the peri-operative dexamethasone group vs placebo (p< 0.001; p=0.002, respectively). Furthermore, pooled active and passive ROM were both statistically significantly improved in the dexamethasone group compared to placebo at 72 hours post-TKA (p<0.001; p=0.001, respectively). In addition, pooled results for the incidence of PONV and total consumption of opioids at 24 and 48 hours post-TKA were both statistically significantly in favour of the dexamethasone group vs placebo (p<0.05 for all). Pooled blood glucose levels were statistically significantly higher in the dexamethasone group at 24 hours follow-up (p<0.001) but not at 72 hours follow-up (p>0.05). Finally, pooled results of length of hospital stay and incidence of complications (i.e., deep vein thrombosis, infection, inadequate wound healing, pulmonary embolism) were not statistically significantly different between the pre-operative dexamethasone group and placebo group (p>0.05 for all).
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
